Exogenous IL-2 Controls the Balance in Th1, Th17, and Treg Cell Distribution in Patients with Progressive Rheumatoid Arthritis Treated with TNF-Alpha Inhibitors

Inflammation

Volumn 38, Issue 2, 2015, Pages 765-774

  Kosmaczewska, Agata ^a   Ciszak, Lidia ^a   Swierkot, Jerzy ^b   Szteblich, Aleksandra ^a   Kosciow, Katarzyna ^c   Frydecka, Irena ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Regional Hospital   (Poland)

Author keywords

in vitro stimulation; iTNF; MTX; rheumatoid arthritis; rIL 2

Indexed keywords

INTERLEUKIN 2; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL STIMULATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; MALE; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CELL CULTURE; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-2; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923847127     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9987-x     Document Type: Article

References (57)

1. Niu, Q., B. Cai, Z.C. Huang, Y.Y. Shi, and L.L. Wang. 2012. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatology International 32: 2731–2736.
2. Wang, W., S. Shao, Z. Jiao, M. Guo, H. Xu, and S. Wang. 2012. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatology International 32: 887–893.
3. Harrington, L.E., R.D. Hatton, P.R. Mangan, H. Turner, T.L. Murphy, and K.M. Murphy. 2005. Interleukin-17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 6: 1123–1132.
4. Beriou, G., C.M. Costantino, C.W. Ashley, L. Yang, V.K. Kuchroo, C. Baecher-Allan, and D.A. Hafler. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113: 4240–4249.
5. Yang, X.O., R. Nurieva, G.J. Martinez, H.S. Kang, Y. Chung, B.P. Pappu, B. Shah, S.H. Chang, K.S. Schluns, S.S. Watowich, X.H. Feng, A.M. Jetten, and C. Dong. 2008. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29: 44–56.
6. Ehrenstein, M.R., J.G. Evans, A. Singh, S. Moore, G. Warnes, D.A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy. Journal of Experimental Medicine 200: 277–285.
7. Lina, C., W. Conghua, L. Nan, and Z. Ping. 2011. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. Journal of Clinical Immunology 31: 596–605.
8. Samson, M., S. Audia, N. Janikashvili, M. Ciudad, M. Trad, J. Fraszczak, P. Ometti, J.F. Maillefert, P. Miossec, and B. Bonnotte. 2012. Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients. Arthritis & Rheumatism 64: 2499–2503.
9. Kelchtermans, H., B. De Klerck, T. Mitera, M. Van Balen, D. Bullens, A. Billiau, G. Leclercq, and P. Matthys. 2005. Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Research & Therapy 7: R402–R415.
10. Setoguchi, R., S. Hori, T. Takahashi, and S. Sakaguchi. 2005. Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. Journal of Experimental Medicine 201: 723–735.
11. Fontenot, J.D., J.P. Rasmussen, M.A. Gavin, and A.Y. Rudensky. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nature Immunology 6: 1142–1151.
12. Li, M.O., Y.Y. Wan, S. Sanjabi, A.K. Robertson, and R.A. Flavell. 2006. Transforming growth factor-beta regulation of immune responses. Annual Review of Immunology 24: 99–146.
13. de la Rosa, M., S. Rutz, H. Dorninger, and A. Scheffold. 2004. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. European Journal of Immunology 34: 2480–2488.
14. Fainboim, L., and L. Arruvito. 2011. Mechanisms involved in the expansion of Tregs during pregnancy: role of IL-2/STAT5 signalling. Journal of Reproductive Immunology 88: 93–98.
15. Zheng, S.G., J. Wang, P. Wang, J.D. Gray, and D.A. Horwitz. 2007. IL-2 is essential for TGF-beta to convert naïve CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. Journal of Immunology 178: 2018–2027.
16. Bluestone, J.A., and A.K. Abbas. 2003. Natural versus adaptive regulatory T cells. Nature Reviews Immunology 3: 253–257.
17. Laurence, A., C.M. Tato, T.S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R.B. Blank, F. Meylan, R. Siegel, L. Hennighausen, E.M. Shevach, and J.J. O’shea. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26: 371–381.
18. Sgouroudis, E., M. Kornete, and C.A. Piccirillo. 2011. IL-2 production by dendritic cells promotes Foxp3+ regulatory T-cell expansion in autoimmune resistant NOD congenic mice. Autoimmunity 44: 406–414.
19. Zhang, H., K.S. Chua, M. Guimond, V. Kapoor, M.V. Brown, T.A. Fleisher, L.M. Long, D. Bernstein, B.J. Hill, D.C. Douek, J.A. Berzofsky, C.S. Carter, E.J. Read, L.J. Helman, and C.L. Mackall. 2005. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nature Medicine 11: 1238–1243.
20. Webster, K.E., S. Walters, R. Kohler, T. Mrkvan, O. Boyman, C.D. Surh, S.T. Grey, and J. Sprent. 2009. In vivo expansion of Treg cells with IL-2 mAb complexes; induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. Journal of Experimental Medicine 206: 751–760.
21. Wilson, M.S., J.T. Pesce, T.R. Ramalingam, R.W. Thompson, A. Cheever, and T.A. Wynn. 2008. Suppression of murine allergic airway disease by IL-2; anti-IL-2 monoclonal antibody-induced regulatory T cells. Journal of Immunology 181: 6942–6954.
22. Grinberg-Bleyer, Y., A. Baeyens, S. You, R. Elhage, G. Fourcade, S. Gregoire, N. Cagnard, W. Carpentier, Q. Tang, J. Bluestone, L. Chatenoud, D. Klatzmann, B.L. Salomon, and E. Piaggio. 2010. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. Journal of Experimental Medicine 207: 1871–1878.
23. Brandenburg, S., T. Takahashi, M. de la Rosa, M. Janke, G. Karsten, T. Muzzulini, Z. Orinska, S. Bulfone-Paus, and A. Scheffold. 2008. IL-2 induces in vivo suppression by CD4+CD25+Foxp3+ regulatory T cells. European Journal of Immunology 38: 1643–1653.
24. Hartemann, A., G. Bensimon, C.A. Payan, S. Jacqueminet, O. Bourron, N. Nicolas, M. Fonfrede, M. Rosenzwajg, C. Bernard, and D. Kaltzmann. 2013. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes & Endocrinology 1: 295–305.
25. Kosmaczewska, A., J. Swierkot, L. Ciszak, A. Szteblich, A. Chrobak, L. Karabon, A. Partyka, J. Szechinski, P. Wiland, and I. Frydecka. 2014. Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment. Rheumatology International 34: 243–253.
26. Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism 31: 315–324.
27. Smolen, J.S., R. Landewe, F.C. Breedveld, M. Dougados, P. Emery, C. Gaujoux-Viala, S. Gorter, R. Knevel, J. Nam, M. Schoels, et al. 2010. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases 69: 964–975.
28. Hennessy, B., J. North, A. Deru, N. Llewellyn-Smith, and M.W. Lowdell. 2001. Use of Leu3a/3b for the accurate determination of CD4 subsets for measurement of intracellular cytokines. Cytometry 44: 148–152.
29. Cope, A.P., M. Londei, N.R. Chu, S.B. Cohen, M.J. Elliott, F.M. Brennan, R.N. Maini, and M. Feldmann. 1994. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. Journal of Clinical Investigation 94: 749–760.
30. Xinqiang, S., L. Fei, L. Nan, L. Yuan, Y. Fang, X. Hong, T. Lixin, L. Juan, Z. Xiao, S. Yuying, and X. Yongzhi. 2010. Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomedicine & Pharmacotherapy 64: 463–471.
31. Blaschke, S., V. Viereck, G. Schwarz, H.M. Klinger, S. Guerluek, and G.A. Müller. 2009. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scandinavian Journal of Rheumatology 38: 235–239.
32. Kawashima, M., and P. Miossec. 2005. mRNA quantification of T-bet, GATA-3, IFN-gamma, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. Journal of Clinical Immunology 25: 209–214.
33. van der Graaff, W.L., A.P.A. Prins, T.M.H. Niers, B.A. Dijkmans, and R.A. van Lier. 1999. Quantification of interferon gamma- and interleukin-4-producing T cells in synovial fluid and peripheral blood of arthritis patients. Rheumatology 38: 214–220.
34. Yamada, H., Y. Nakashima, K. Okazaki, T. Mawatari, J.I. Fukushi, N. Kaibara, A. Hori, Y. Iwamoto, and Y. Yoshikai. 2008. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 67: 1299–1304.
35. Thornton, A.M., E.E. Donovan, C.A. Piccirillo, and E.M. Shevach. 2004. IL-2 is critically required for the in vitro activation of CD4+CD256+ T cell suppressor function. Journal of Immunology 172: 6519–6523.
36. Flores Borja, F., E.C. Jury, C. Mauri, and M.R. Ehrenstein. 2008. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proceedings of the National Academy of Sciences USA 105: 19396–19401.
37. Stummvoll, G.H., R.J. DiPaolo, E.N. Huter, T.S. Davidson, D. Glass, J.M. Ward, and E.M. Shevach. 2008. Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. Journal of Immunology 181: 1908–1916.
38. Chauhan, S.K., J. El Annan, T. Ecoiffier, S. Goyal, Q. Zhang, D.R. Saban, and R. Dana. 2009. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. Journal of Immunology 182: 1247–1252.
39. Vercoulen, Y., E.J. Wehrens, N.H. van Teijlingen, W. de Jager, J.M. Beekman, and B.J. Prakken. 2009. Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells. PLoS ONE 4: e7183.
40. Kryczek, I., S. Wei, L. Vatan, J. Escara-Wilke, W. Szeliga, E.T. Keller, and W. Zou. 2007. Opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool. IL-1 subverts IL-2-mediated suppression. Journal of Immunology 179: 1423–1426.
41. Matsuyama, Y., H. Okazaki, M. Hoshino, S. Onishi, Y. Kamata, K. Nagatani, T. Nagashima, M. Iwamoto, T. Yoshio, H. Ohto-Ozaki, H. Tamemoto, M. Komine, H. Sekiya, S. Tominaga, and S. Minota. 2012. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1beta signaling and a poor clinical response. Rheumatology International 32: 1397–1401.
42. Benson, A., S. Murray, P. Divakar, N. Burnaevskiy, R. Pifer, J. Forman, and F. Yarovinsky. 2012. Microbial infection-induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism. Journal of Immunology 188: 800–810.
43. Berretta, F., J. St-Pierre, C.A. Piccirillo, and M.M. Stevenson. 2011. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection. Journal of Immunology 186: 4862–4871.
44. Zheng, S.G., J. Wang, and D.A. Horwitz. 2008. Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. Journal of Immunology 180: 7112–7116.
45. Todd, J.A., N.M. Walker, J.D. Cooper, D.J. Smyth, K. Downes, V. Plagnol, R. Bailey, S. Nejentsev, S.F. Field, F. Payne, et al. 2007. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nature Genetics 39: 857–864.
46. Yamanouchi, J., D. Rainbow, P. Serra, S. Howlett, K. Hunter, V.E. Garner, A. Gonzalez-Munoz, J. Clark, R. Veijola, R. Cubbon, et al. 2007. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nature Genetics 39: 329–337.
47. Sgouroudis, E., A. Albanese, and C.A. Piccirillo. 2008. Impact of protective IL-2 allelic variants on CD4+Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. Journal of Immunology 181: 6283–6292.
48. Tang, Q., J.Y. Adams, C. Penaranda, K. Melli, E. Piaggio, E. Sgouroudis, C.A. Piccirillo, B.L. Salomon, and J.A. Bluestone. 2008. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687–697.
49. Tenorio, E.P., J. Fernandez, C. Castellanos, J.E. Olguín, and R. Saavedra. 2011. CD4+ Foxp3+ regulatory T cells mediate Toxoplasma gondii-induced T-cell suppression through an IL-2-related mechanism but independently of IL-10. European Journal of Immunology 41: 3529–3541.
50. Kryczek, I., S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, and W. Zou. 2007. Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. Journal of Immunology 178: 6730–6733.
51. Zago, C.A., K.R. Bortoluci, L.R. Sardinha, F.D. Pretel, S.I. Castillo-Méndez, A.P. Freitas do Rosário, M.I. Hiyane, S.M. Muxel, S.M. Rodriguez-Málaga, I.A. Abrahamsohn, J.M. Álvarez, and M.R. D’Império Lima. 2012. Anti-IL-2 treatment impairs the expansion of Treg cell population during acute malaria and enhances the Th1 cell response at the chronic disease. PLoS ONE 7: e29894
52. Dinh, T.N., T.S. Kyaw, P. Kanellakis, K. To, P. Tipping, B.H. Toh, A. Bobik, and A. Agrotis. 2012. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Circulation 126: 1256–1266.
53. Andersen, M.H., J. Gehl, S. Reker, L.Ø. Pedersen, J.C. Becker, P. Geertsen, and P. thor Straten. 2003. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Seminars in Cancer Biology 13: 449–459
54. Slingluff, C.L. Jr, G.R. Petroni, G.V. Yamshchikov, S. Hibbitts, W.W. Grosh, K.A. Chianese-Bullock, E.A. Bissonette, D.L. Barnd, D.H. Deacon, J.W. Patterson, J. Parekh, P.Y. Neese, E.M. Woodson, C.J. Wiernasz, and P. Merrill. 2004. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus interleukin-2 administered either concurrently or on a delayed schedule. Journal of Clinical Oncology 22: 4474–4485
55. Escobar, A., M. Lopez, A. Serrano, M. Ramirez, C. Pérez, A. Aguirre, R. González, J. Alfaro, M. Larrondo, M. Fodor, C. Ferrada, and F. Salazar-Onfray. 2005. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clinical and Experimental Immunology 142: 555–568.
56. Koreth, J., K. Matsuoka, H. Kim, S.M. McDonough, B. Bindra, E.P. Alyea 3rd, P. Armand, C. Cutler, V.T. Ho, N.S. Treister, D.C. Bienfang, S. Prasad, D. Tzachanis, R.M. Joyce, D.E. Avigan, J.H. Antin, J. Ritz, and R.J. Soiffer. 2011. Interleukin-2 and regulatory T cells in graft-versus-host disease. New England Journal of Medicine 365: 2055–2066.
57. Saadoun, D., M. Rosenzwajg, F. Joly, A. Six, F. Carrat, V. Thibault, D. Sene, P. Cacoub, and D. Klatzmann. 2011. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. New England Journal of Medicine 365: 2067–2077.